Insights On Upstream Manufacturing
-
IND In As Little As 6 Months: Now Beyond mAbs - Accelerating Bispecifics, Fc-Fusions And High-Concentration Biologics To The Clinic
9/25/2026
Listen as our experts outline expanded accelerated DNA-to-IND pathways for a broader range of biologic modalities, examining how expression technologies and integrated CMC strategies can shorten development timelines.
-
Behind The Data: Engineering Hepatocyte-Targeted LNPs
9/23/2026
See how lipid nanoparticle platforms can deliver RNA and large DNA payloads to primary human T cells, improving transfection, expression durability, and CAR insertion efficiency.
-
Behind The Data: Comprehensive Off-Target Assessment Strategies
9/23/2026
Explore how biochemical, computational, and cell-based methods can identify, confirm, and interpret off-target editing risks, providing a more complete safety assessment for CRISPR-based therapeutics.
-
A Novel Non-Viral Platform For High-Efficiency T-Cell Engineering
9/22/2026
Gain insight into how nuclease format, delivery method, and DNA template design influence knockout efficiency, targeted TCR integration, cell viability, and recovery.
-
Perfusion Cultivations With NIST CHO Cells Using The Multifors 3 Bioreactor
9/22/2026
Execute stable long-term perfusion with automated volume, feed, and biomass control. Maintain cell viability and high volumetric productivity with integrated bioreactor systems.
-
Discovery And Validation Of High-Efficiency Large Serine Recombinases
9/22/2026
Novel large serine recombinases demonstrate efficient targeted gene insertion across mammalian cell types. Learn how bioinformatic discovery can expand the toolkit for delivering large payloads.
-
Discovery And Validation Of Novel Large Serine Recombinases
9/22/2026
Discover how bioinformatics, machine learning, and protein engineering can advance programmable gene insertion, with novel recombinases demonstrating strong mammalian-cell activity.
-
Why Isn't One Assay Enough For Gene Editing Off-Target Safety Assessment?
9/22/2026
Gene editing off-target risk cannot be captured by one assay. Combining biochemical, computational, and cell-based methods with deep sequencing provides a more complete view of potential edits.
-
Challenges And Opportunities For MSC Expansion Workflows
9/22/2026
Discover how optimizing cell culture platforms and closed systems reduces manufacturing costs, improves media efficiency, and supports scalable stem cell production.
-
Metabolic Shift Monitoring Of Immune Cells During Differentiation
9/22/2026
Real-time tracking of glucose and lactate kinetics reveals critical metabolic shifts during immune cell differentiation, enabling quantitative evaluation of cellular state changes.